Catalyst Calendar

Tue, Aug 4, 2026

1 updates

7:00 AM

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and

lisata.com

Wed, Jun 10, 2026

1 updates

LSTA

8:00 AM

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction

lisata.com